Zealand Pharma A-S
Closed
306.5 -1.64
Overview
Share price change
24h
Min
303.39
Max
319.39
Income | 4.3B 3.9B |
|---|---|
Sales | 4.5B 4.5B |
P/E Sector Avg | 7.665 56.659 |
EPS | 55.34 |
Profit margin | 87.219 |
Employees | 578 |
EBITDA | 4.2B 3.9B |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +25.15% upside |
Next Earnings | 12 Nov 2026 |
|---|
Market Cap | -1.9B 20B |
|---|---|
Previous open | 308.14 |
Previous close | 306.5 |
Zealand Pharma A-S Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Zealand Pharma A-S Forecast
Price Target
By TipRanks
25.15% upside
12 Months Forecast
Average 270.582 DKK 25.15%
High 270.568 DKK
Low 270.568 DKK
Based on 1 Wall Street analysts offering 12 month price targets forZealand Pharma A-S - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Zealand Pharma A-S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.